The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

Manry J,Bastard P,Gervais A,Le Voyer T,Rosain J,Philippot Q,Michailidis E,Hoffmann H,Eto S,Garcia-Prat M,Bizien L,Parra-Martínez A,Yang R,Haljasmägi L,Migaud M,Särekannu K,Maslovskaja J,de Prost N,Tandjaoui-Lambiotte Y,Luyt C,Amador-Borrero B,Gaudet A,Poissy J,Morel P,Richard P,Cognasse F,Troya J,Trouillet-Assant S,Belot A,Saker K,Garçon P,Rivière J,Lagier J,Gentile S,Rosen L,Shaw E,Morio T,Tanaka J,Dalmau D,Tharaux P,Sene D,Stepanian A,Mégarbane B,Triantafyllia V,Fekkar A,Heath J,Franco J,Anaya J,Solé-Violán J,Imberti L,Biondi A,Bonfanti P,Castagnoli R,Delmonte O,Zhang Y,Snow A,Holland S,Biggs C,Moncada-Vélez M,Arias A,Lorenzo L,Boucherit S,Anglicheau D,Planas A,Haerynck F,Duvlis S,Ozcelik T,Keles S,Bousfiha A,El Bakkouri J,Ramirez-Santana C,Paul S,Pan-Hammarström Q,Hammarström L,Dupont A,Kurolap A,Metz C,Aiuti A,Casari G,Lampasona V,Ciceri F,Barreiros L,Dominguez-Garrido E,Vidigal M,Zatz M,van de Beek D,Sahanic S,Tancevski I,Stepanovskyy Y,Boyarchuk O,Nukui Y,Tsumura M,Vidaur L,Tangye S,Burrel S,Duffy D,Quintana-Murci L,Klocperk A,Kann N,Shcherbina A,Lau Y,Leung D,Coulongeat M,Marlet J,Koning R,Reyes L,Chauvineau-Grenier A,Venet F,Monneret G,Nussenzweig M,Arrestier R,Boudhabhay I,Baris-Feldman H,Hagin D,Wauters J,Meyts I,Dyer A,Kennelly S,Bourke N,Halwani R,Sharif-Askari F,Dorgham K,Sallette J,Sedkaoui S,AlKhater S,Rigo-Bonnin R,Morandeira F,Roussel L,Vinh D,Erikstrup C,Condino-Neto A,Prando C,Bondarenko A,Spaan A,Gilardin L,Fellay J,Lyonnet S,Bilguvar K,Lifton R,Mane S,Anderson M,Boisson B,Béziat V,Zhang S,Andreakos E,Hermine O,Pujol A,Peterson P,Mogensen T,Rowen L,Mond J,Debette S,de Lamballerie X,Burdet C,Bouadma L,Zins M,Soler-Palacin P,Colobran R,Gorochov G,Solanich X,Susen S,Martinez-Picado J,Raoult D,Vasse M,Gregersen P,Piemonti L,Rodríguez-Gallego C,Notarangelo L,Su H,Kisand K,Okada S,Puel A,Jouanguy E,Rice C,Tiberghien P,Zhang Q,Casanova J,Abel L,Cobat A

Source :

2022 Mai 16

Pmid / DOI:

35576468

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged 4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals

Voir la publication

Toutes les publications